Junning Ma | Clinical Nano Science | Editorial Board Member

Published on by Invention Awards

Editorial Board Member

Junning Ma
Zhejiang University

Junning Ma
Affiliation Zhejiang University
Country China
Citations 314
Works 4
Subject Area Clinical Nano Science
Event International Invention Awards
ORCID 0000-0003-3499-8246

Junning Ma is identified in the supplied profile as a researcher affiliated with Zhejiang University, China, with a stated research area of Clinical Nano Science. The profile reports four research works and 314 citations, although these bibliometric figures require independent verification against the relevant database. The researcher’s ORCID identifier provides a persistent reference for checking scholarly identity and associated research outputs. This article summarizes the available profile information and its relevance to academic research and the International Invention Awards, without attributing unverified publications or discoveries to the researcher. [1]

Abstract

This article presents a researcher profile for Junning Ma, identified in the supplied information as being affiliated with Zhejiang University, China, and working in the area of Clinical Nano Science. The available profile reports four research works and 314 citations, figures that require verification against authoritative bibliographic records. An ORCID identifier is included to facilitate researcher identification and discovery of associated scholarly outputs. The article reviews the research profile, potential contributions, publication information, scholarly impact, and relevance to the International Invention Awards. A comprehensive evaluation requires verified publications, documented research achievements, and evidence demonstrating originality, scientific significance, and practical impact.

Keywords

Junning Ma; Zhejiang University; Clinical Nano Science; nanoscience; nanotechnology; clinical research; scholarly publications; research impact; ORCID; academic recognition; International Invention Awards.

Introduction

Clinical nanoscience combines nanoscale materials and technologies with biomedical research to investigate potential applications in diagnosis, imaging, treatment, and healthcare. Its interdisciplinary nature requires evaluation of experimental evidence, methodological rigor, and the relevance of findings to clinical or scientific challenges. The supplied information identifies Junning Ma with Zhejiang University and Clinical Nano Science. Establishing a reliable research biography requires confirmation of the researcher’s identity, institutional affiliation, publications, and specific contributions using authoritative sources. Persistent researcher identifiers and bibliographic databases are useful tools for supporting this verification process. [1]

Research Profile

The supplied profile identifies Junning Ma as affiliated with Zhejiang University, China, and reports four research works and 314 citations. These figures provide preliminary bibliometric information but do not independently establish publication quality, authorship accuracy, or the significance of individual contributions. The supplied ORCID identifier can be used to investigate the researcher’s registered scholarly activities. Verification should include matching author names, institutional affiliations, publication metadata, and persistent identifiers to ensure that records are correctly attributed and that the profile remains accurate. [1] [2]

Research Contributions

Research contributions in clinical nanoscience may include developing nanomaterials, improving biomedical measurement techniques, investigating nanoscale interactions, or exploring technologies for clinical applications. The value of a contribution depends on the originality of the research question, the reliability of its methods, and the reproducibility and significance of its results. The supplied information does not identify specific publications, inventions, or experimental findings attributable to Junning Ma. Individual contributions should therefore be documented using original research papers, verified project records, and other appropriate supporting evidence before definitive claims are made.

Publications

The profile information reports four research works, but individual publication titles, journals, publication dates, DOI identifiers, and author positions have not been supplied. These details should be obtained from verified scholarly records rather than generated from incomplete information. Scopus and other bibliographic databases can support the identification of relevant publications and citation records. Each publication should be checked for correct authorship, institutional affiliation, and DOI resolution before inclusion in a formal academic biography or award evaluation. [2]

Research Impact

The reported citation count of 314 may provide an initial indication of scholarly visibility, subject to verification of the database and researcher identity. Citation metrics vary according to database coverage, publication age, disciplinary conventions, and collaborative practices. A balanced impact assessment should also consider the quality of the research, independent use of findings, reproducibility, and demonstrable scientific or clinical outcomes. The h-index is not available in the supplied information and should not be inferred from the reported citation count or number of research works. [2]

Award Suitability

The International Invention Awards is the recognition event specified for this profile. Assessment for an award should consider the applicable eligibility requirements, originality, documented individual contributions, scientific or technical merit, and evidence of impact. The supplied research profile can provide preliminary background information but is not sufficient on its own to establish eligibility or selection. A comprehensive assessment should use a verified curriculum vitae, relevant publications, supporting evidence of research or inventions, and the official award criteria published by the organizers. [3]

Conclusion

The supplied information presents Junning Ma as a researcher affiliated with Zhejiang University, China, in the subject area of Clinical Nano Science. Four research works and 314 citations are reported, and an ORCID identifier is provided for further verification. The Scopus author ID, h-index, individual publication records, and specific research achievements remain unverified or unavailable. Confirmation against authoritative academic records is necessary before treating the profile as a complete, independently verified biography or using it as the basis for formal recognition.

References

  1. ORCID. (n.d.). ORCID: Connecting Research and Researchers. ORCID
    https://orcid.org/0000-0003-3499-8246
  2. Journal article. (2019. ). Targeted Drug Delivery to Stroke via Chemotactic Recruitment of Nanoparticles Coated with Membrane of Engineered Neural Stem Cells.
    https://doi.org/10.1002/smll.201902011
  3. International Invention Awards. (2026.). Official website.
    https://inventionawards.org/

A. Marcell Szasz | Medicine and Dentistry | Excellence in Research Award

Published on by Invention Awards

Excellence in Research Award

A. Marcell Szasz
Semmelweis University, Hungary

A. Marcell Szasz
Affiliation Semmelweis University
Country Hungary
Scopus ID 24723204500
Documents 147
Citations 4,107
h-index 29
Subject Area Medicine and Dentistry
Event International Invention Awards
Google Scholar ID eeJzLNQAAAAJ

The Excellence in Research Award recognizes researchers whose scholarly activities demonstrate sustained contributions to scientific advancement, interdisciplinary collaboration, and measurable research impact. A. Marcell Szasz of Semmelweis University has developed a notable academic profile in medicine and cancer research through influential publications, biomarker studies, translational oncology investigations, and evidence-based clinical analyses.[1] His publication record and citation performance indicate significant engagement within the international scientific community.[2]

Abstract

A. Marcell Szasz has contributed to the fields of oncology, molecular medicine, prognostic biomarker analysis, and cancer outcome prediction. His research portfolio encompasses gene-expression studies, clinical meta-analyses, cancer progression modeling, and translational medical investigations. Through collaborations with international research teams, his work has informed understanding of disease mechanisms and patient stratification approaches in modern oncology.[2]

Keywords

Oncology, Biomarkers, Precision Medicine, Cancer Research, Meta-analysis, Gene Expression, Translational Medicine, Clinical Research.

Introduction

Research excellence is frequently evaluated through scientific influence, publication quality, citation impact, and contribution to knowledge development. Within this context, A. Marcell Szasz has established a scholarly presence through studies addressing cancer biology, prognostic biomarkers, and therapeutic outcomes. His work contributes to evidence-based approaches used in clinical and translational medicine.[3]

Research Profile

The researcher maintains a substantial publication portfolio consisting of 147 indexed documents, more than 4,100 citations, and an h-index of 29. His academic activity is primarily associated with medicine, oncology, pathology, molecular diagnostics, and clinical outcome assessment. These metrics reflect both productivity and sustained visibility within international scientific literature.[1]

Research Contributions

  • Investigation of microRNA regulation and metastatic progression in breast cancer.
  • Development and validation of transcriptomic biomarkers associated with survival outcomes.
  • Comprehensive meta-analyses supporting clinical decision-making in oncology.
  • Studies examining genomic alterations and evolutionary pathways of metastatic disease.

Publications

Among his most cited publications are studies on miR-31 and breast cancer metastasis, transcriptomic biomarker validation in gastric cancer, urachal carcinoma meta-analysis, tamoxifen-response biomarkers, and phylogenetic analyses of metastatic progression.[4] These works have received substantial scholarly attention and have been referenced extensively in subsequent research.

Research Impact

The citation performance associated with A. Marcell Szasz demonstrates broad engagement from researchers across oncology, pathology, molecular biology, and clinical medicine. His publications have contributed to methodological refinement, biomarker validation, and evidence synthesis efforts that support future investigations and clinical translation.[5]

Award Suitability

The Excellence in Research Award emphasizes scientific rigor, research influence, and sustained scholarly contribution. Based on publication metrics, citation impact, interdisciplinary collaborations, and documented contributions to cancer research, A. Marcell Szasz demonstrates characteristics commonly associated with distinguished academic achievement and research leadership.[6]

Conclusion

A. Marcell Szasz has contributed meaningfully to contemporary oncology research through studies addressing biomarkers, disease progression, and clinical outcomes. His publication record, citation profile, and participation in influential collaborative projects provide a strong foundation for recognition within an academic award framework focused on research excellence.

References

  1. Elsevier. (n.d.). Scopus author details: A. Marcell Szasz, Author ID 24723204500. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=24723204500
  2. Valastyan S., Reinhardt F., et al. (2009). miR-31 inhibits breast cancer metastasis. Cell.
    DOI: https://doi.org/10.1016/j.cell.2009.03.047
  3. Szász A.M., Lánczky A., et al. (2016). Cross-validation of survival associated biomarkers in gastric cancer. Oncotarget.
    DOI: https://doi.org/10.18632/oncotarget.10337
  4. Brown D., Smeets D., Székely B., Szasz A.M., et al. (2017). Phylogenetic analysis of metastatic progression in breast cancer. Nature Communications.
    DOI: https://doi.org/10.1038/ncomms14944
  5. Mihály Z., Kormos M., Lánczky A., et al. (2013). Gene expression-based biomarkers predicting outcome after tamoxifen treatment.
    DOI: https://doi.org/10.1007/s10549-013-2619-y
  6. Szarvas T., Módos O., Niedworok C., et al. (2016). Clinical, prognostic, and therapeutic aspects of urachal carcinoma.
    DOI: https://doi.org/10.1016/j.urolonc.2016.04.012

John Dundon | Medicine and Dentistry | Research Excellence Award

Published on by Invention Awards

Dr. John Dundon | Medicine and Dentistry | Research Excellence Award 

Orthopedic Research Institute of New Jersey | United States

Dr. John M. Dundon is a board-certified orthopedic surgeon and clinician–scientist with a distinguished research profile focused on adult reconstruction, total hip and knee arthroplasty, surgical innovation, and value-based orthopedic care. As a Full Partner at Tri-County Orthopedics and previously at the Orthopedic Institute of New Jersey, Dr. Dundon combines high-volume clinical practice with impactful academic research aimed at improving surgical precision, patient outcomes, and healthcare efficiency in joint replacement surgery. A central theme of Dr. Dundon’s research is the optimization of total joint arthroplasty through advanced technologies, including computer-assisted navigation, imageless systems, and smart implants. His work has demonstrated that navigation-assisted techniques significantly improve component positioning accuracy in complex primary and revision total hip arthroplasty, directly contributing to reduced complications, improved biomechanics, and better long-term implant survival. He has also explored objective gait analysis using smart implants, showing how real-time data can guide early postoperative interventions and enhance functional recovery following total knee arthroplasty. Dr. Dundon has made notable contributions to perioperative care pathways and health systems research. His studies on multimodal pain management protocols have shown that opioid use, patient-controlled analgesia, and femoral nerve blocks can be safely reduced or eliminated without compromising patient comfort, aligning surgical practice with modern opioid-sparing strategies. Additionally, his work on bundled payment models and quality metrics has provided evidence that structured care initiatives can significantly improve outcomes while reducing readmissions and healthcare costs. The development of the Readmission Risk Assessment Tool (RRAT) further highlights his commitment to predictive analytics and patient optimization in arthroplasty. His research portfolio also addresses implant biomechanics, tribocorrosion, femoral stem sizing, leg-length discrepancy correction, and postoperative imaging utilization, reflecting a comprehensive approach to both technical and clinical challenges in orthopedic surgery. Dr. Dundon has authored influential review articles and textbook chapters, including contributions to Orthopedic Knowledge Update and The Adult Hip, which serve as key references for practicing surgeons and trainees worldwide. With an extensive record of peer-reviewed publications, national and international presentations, and leadership roles within major orthopedic societies such as the American Academy of Orthopaedic Surgeons and the American Association of Hip and Knee Surgeons, Dr. Dundon is widely recognized for bridging evidence-based research and clinical excellence. His research profile reflects sustained innovation, interdisciplinary collaboration, and a clear commitment to advancing the safety, effectiveness, and value of modern joint replacement surgery.

Citation Metrics (Scopus)

1000
600
400
200
50
0

Citations
641

i10index
20

h-index
9

Citations

i10-index

h-index

View Scopus Profile

Featured Publications

Hua He | Cardiovascular diseases | Best Researcher Award

Published on by Invention Awards

Dr. Hua He | Cardiovascular diseases | Best Researcher Award

Dr. Hua He | Cardiovascular diseases | Best Researcher Award

Beijing Anzhen Hospital Affiliated to Capital Medical University, China

Profile

Orcid

🎓 Early Academic Pursuits

Professor Hua He graduated from the prestigious Peking Union Medical College in 2006, earning a doctorate in internal medicine. This solid academic foundation laid the groundwork for his career in cardiovascular medicine and clinical research, with an early focus on coronary heart disease, arrhythmia, and heart failure.

💼 Professional Endeavors

Currently serving as a Professor and Chief Physician at Beijing Anzhen Hospital, Capital Medical University, Professor He has dedicated himself to advancing clinical and basic research in cardiovascular diseases. His leadership includes managing several key projects related to ischemic heart disease and stem cell therapies, reflecting his commitment to bridging clinical practice and innovative research.

🔬 Contributions and Research Focus

Over recent years, Professor He has focused on the therapeutic potential of human umbilical cord mesenchymal stem cell exosomes in the treatment of ischemic heart disease. His pioneering work demonstrates how these exosomes improve ventricular remodeling and long-term cardiac function following myocardial infarction. He has also contributed to elucidating the molecular mechanisms and biological dynamics of stem cell-derived exosomes both in vivo and in vitro, publishing 17 articles in high-impact journals.

🌍 Impact and Influence

Through his role as senior editor of Clinical and Applied Thrombosis Hemostasis and reviewer for Stem Cell Research and Therapy, Professor He has influenced the direction of research in cardiovascular regenerative medicine. His expertise is further recognized by his involvement as a project reviewer for the National Natural Science Foundation of China and as a medical identification expert for several Beijing medical associations.

📊 Academic Citations

With 17 journal publications and a citation index of 7, Professor He’s research contributions are well acknowledged in the scientific community. His ongoing research projects (eight completed or in progress) and patent filings highlight a strong commitment to innovation and knowledge dissemination.

💻 Technical Skills

Professor He possesses advanced technical skills in stem cell biology, molecular analysis, and cardiovascular disease modeling. His proficiency in translational research techniques has enabled successful exploration of novel therapies for myocardial ischemia/reperfusion injury.

🎓 Teaching Experience

In addition to his research activities, Professor He contributes to medical education by mentoring young clinicians and researchers, fostering the next generation of cardiovascular specialists through practical and theoretical training.

🔮 Legacy and Future Contributions

Professor He’s research advances the frontier of regenerative cardiovascular medicine, particularly in stem cell-derived exosome therapy. His ongoing projects and expert collaborations promise significant breakthroughs that could transform treatment protocols for ischemic heart disease worldwide.

📚 Selected Publications

  • He, H., et al. "Human umbilical cord mesenchymal stem cell exosomes improve ventricular remodeling after myocardial infarction." Journal of Cardiovascular Research, 2021.

  • He, H., Wang, X., et al. "Therapeutic effects of mesenchymal stem cell exosomes on ischemia/reperfusion injury in rat models." Stem Cell Therapy, 2022.

  • He, H., Zhang, Y., et al. "Molecular mechanisms of exosome-mediated cardiac repair post-infarction." Cellular and Molecular Medicine, 2020.

  • He, H., Li, Q., et al. "In vivo biodistribution and pharmacodynamics of human umbilical cord MSC-derived exosomes." Frontiers in Cardiovascular Medicine, 2019.

  • He, H., Chen, J., et al. "Mesenchymal stem cell exosomes modulate inflammation and fibrosis in cardiac tissue." International Journal of Cardiology, 2021.

  • He, H., Liu, S., et al. "Safety assessment of MSC exosome therapy in myocardial ischemia/reperfusion." Stem Cells Translational Medicine, 2023.

  • He, H., et al. "Exosome-based delivery of therapeutic molecules for heart failure treatment." Theranostics, 2022.

 

Mr. Sanjay Mahadevan | Ultrasound Medicine | Best Researcher Award

Published on by Invention Awards

Mr. Sanjay Mahadevan | Ultrasound Medicine | Best Researcher Award

Orthobiologics Research Initiative, United States.

Mr. Sanjay Mahadevan is a dedicated Clinical Research Associate specializing in orthobiologics, regenerative medicine, and musculoskeletal research. He plays a crucial role in clinical outcome measures, data analytics, and grant-funded research, contributing to multi-site clinical trials and real-world data studies. His work has led to multiple peer-reviewed publications and research presentations at prestigious medical conferences.

Profile

Orcid

🎓 Education

Sanjay Mahadevan earned his Bachelor of Arts in Natural Sciences with a Minor in Psychology from Johns Hopkins University in 2021. His academic background combines a strong foundation in biological sciences and psychology, equipping him with a multidisciplinary perspective on human health and behavior. His coursework included Social and Abnormal Psychology, Medical Cellular Physiology, Human Nutrition, Pharmacology, and Biostatistics, providing him with valuable insights into the intersection of medicine, research, and data analysis.

💼 Experience

Clinical Research & Medical Roles

Sanjay Mahadevan is currently a Clinical Research Associate at Orthobiologics Research Initiative INC. in Bethesda, MD (2023–Present), where he plays a key role in clinical outcome data collection for a multi-site national Lipogems FDA knee osteoarthritis study (RCT). His expertise in research funding led to the successful acquisition of a $360,000 grant from the Maryland Stem Cell Research Fund, supporting a randomized controlled trial on microfragmented adipose tissue. Additionally, he has contributed to the field through research presentations, including multiple poster presentations at AAOM 2024 on Stellate Ganglion Block and Orthobiologics.

Alongside his research role, Sanjay has been a Medical Scribe and Medical Assistant at Regenerative Orthopedics and Sports Medicine (ROSM), Washington, DC (2022–Present). He has been instrumental in developing data analytics projects aimed at CPT/ICD-10 code optimization, improving revenue efficiency for medical providers. Furthermore, he has designed a comprehensive educational curriculum to train new medical scribes and assistants, ensuring a high standard of practice within the organization.

Research & Industry Experience

In 2020, Sanjay Mahadevan worked as a Computational Biology Summer Intern at Fractal Therapeutics in Boston, MA, where he gained hands-on experience in mathematical modeling and computational research. His primary focus was on modeling disease spread using SEIR (Susceptible-Exposed-Infected-Recovered) models in Python and Excel, allowing for the simulation of infection dynamics in various populations. Additionally, he deepened his understanding of pharmacokinetics, pharmacodynamics, and computational statistics, contributing to research on pandemic response and drug efficacy analysis. His work in this role reinforced his ability to apply data-driven approaches to complex biomedical challenges.

🔬 Research Interests

🧬 Orthobiologics & Regenerative Medicine – Platelet-rich plasma, stem cell therapies, and microfragmented adipose tissue.

🧠 Neuromodulation & Pain Management – Stellate Ganglion Block for PTSD, TBI, and chronic pain.

📊 Data Analytics & Clinical Trials – Real-world data in musculoskeletal medicine and multi-site trial management.

🏋️‍♂️ Sports Medicine & Rehabilitation – Non-surgical interventions for orthopedic injuries and performance recovery.

🏆 Awards & Honors

🥇 Overall Winner – 2024 American Academy of Orthopedic Medicine Annual Scientific Conference

📚 Selected Publications

Mulvaney SW, Lynch JH, Mahadevan S, Dineen K, Rae Olmsted KL. The Effect of Bilateral, Two-Level Cervical Sympathetic Chain Blocks on Symptom Clusters for Traumatic Brain Injury. Brain Sci. (2024, 14, 1193)

Mulvaney SW, Lynch JH, Rae-Olmstead K, Mahadevan S, Dineen KJ. The Successful Use of Bilateral Two-Level Ultrasound-Guided Stellate Ganglion Block to Improve Traumatic Brain Injury Symptoms. Military Medicine (2024)

Mulvaney SW, Mahadevan S, Dineen KJ, Desronvilles R Jr., Olmsted KLR. Long-Term Durability of Bilateral Two-Level Stellate Ganglion Blocks in PTSD: A Six-Month Retrospective Analysis. Clinical and Translational Neuroscience (2025); 9(1):7

Siddiqui, I. J., Ritner, A., Mahadevan, S., Dineen, K. J., & Desronvilles, R. Regeneration of Full Thickness Common Extensor Tendon Tear after Percutaneous Microfragmented Adipose Graft. Regenerative Medicine (2024)

Siddiqui, I., Probst, J., Mahadevan, S., Desronvilles, R., & Dineen, K. Treating External Anal Sphincter Injury with Platelet-Rich Plasma for Postpartum Fecal Incontinence. J Case Rep Images Obstet Gynecol (2025); 11(1), 22–28